89 results
Search Results
2. Welcome to Seminars in Thrombosis and Hemostasis 2020—New (2018) Impact Factor and Most Highly Cited Papers.
- Subjects
- *
HEMOSTASIS , *THROMBOSIS , *VON Willebrand disease , *ANTIPHOSPHOLIPID syndrome , *CONGENITAL disorders , *SINGLE-photon emission computed tomography - Published
- 2020
- Full Text
- View/download PDF
3. Antiphospholipid Syndrome Nephropathy Occurs in Pregnancy: A Case Report.
- Author
-
Ji, Chao, Wang, Yakun, Zhai, Xiaoxiao, and Ji, Guoxin
- Abstract
Objective: This paper presents an analysis of the pregnancy trajectory and therapeutic regimen documentation of a primigravida with APSN. It aims at communicating the therapeutic approach and preventive measures for APSN in pregnancy. Case Presentation: This paper reports the trajectory and therapeutic regimen documentation of a primigravida with APSN. The APSN was discovered in a primigravida woman aged 26 years at 11 weeks of gestation. The initial therapy regimen consists of daily administration of prednisone 10 mg, hydroxychloroquine 200 mg, dapparin 5000 IU, and aspirin 50 mg. At a gestational age of 20 + 3 weeks, the dosage of dapparin was modified to 5000 IU/other day, along with a significant rise in urinary protein level seen at 30 + 3 weeks of gestational age. The initial dosage of dapanin sodium was renewed. The patient delivered at 38 + 3 weeks of gestation without other complications. Conclusion: It is imperative to acknowledge that altering the dosage and administration of medication should not be done haphazardly during pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The Most Highly Downloaded Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 10 Years in the Making.
- Author
-
Favaloro, Emmanuel J.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *THROMBOTIC thrombocytopenic purpura , *HEMOSTASIS , *THROMBOSIS , *DISSEMINATED intravascular coagulation , *DATA analysis - Abstract
This document is an editorial celebrating the 50th anniversary of Seminars in Thrombosis and Hemostasis (STH), a medical journal that first published in 1974. The editorial discusses the various celebratory issues that have been published over the years, which contain historical content related to the fields of thrombosis and hemostasis. The document also mentions the republishing of highly cited and downloaded papers from STH, along with accompanying commentaries from experts in the respective fields. Additionally, the document provides a list of the 50 most highly downloaded papers from STH between 2014 and 2023. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. The Etiology of the Thrombotic Phenomena Involved in the Process of Coronary Artery Disease—What Is the Role of Thrombophilic Genes in the Development of This Pathology?
- Author
-
Bararu Bojan, Iris, Dobreanu, Stefan, Vladeanu, Maria Cristina, Ciocoiu, Manuela, Badescu, Codruta, Plesoianu, Carmen, Filip, Nina, Iliescu, Dan, Frasinariu, Otilia, Bojan, Andrei, Tudor, Razvan, and Badulescu, Oana Viola
- Subjects
- *
CORONARY artery disease , *ETIOLOGY of diseases , *FACTOR V Leiden , *CORONARY thrombosis , *PATHOLOGY - Abstract
Cardiovascular diseases, among which includes coronary artery disease, represent one of the most important causes of mortality and morbidity worldwide. Research aimed at determining the risk factors involved recognizes a group of "traditional" risk factors, but also more recent studies identified over 100 "novel" ones which may have a role in the disease. Among the latter is the thrombophilia profile of a patient, a pathology well-established for its involvement in venous thromboembolism, but with less studied implications in arterial thrombosis. This paper reviews the literature, explaining the pathophysiology of the thrombophilia causes associated most with coronary thrombosis events. Results of several studies on the subject, including a meta-analysis with over 60,000 subjects, determined the significant involvement of factor V Leiden, prothrombin G20210A mutation, plasminogen activator inhibitor–1 and antiphospholipid syndrome in the development of coronary artery disease. The mechanisms involved are currently at different stages of research, with some already established and used as therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Promoting awareness of terminology related to unmet medical needs in context of rheumatic diseases in Japan: a systematic review for evaluating unmet medical needs.
- Author
-
Yamazaki, Susumu, Izawa, Kazushi, Matsushita, Masakazu, Moriichi, Akinori, Kishida, Dai, Yoshifuji, Hajime, Yamaji, Ken, Nishikomori, Ryuta, Mori, Masaaki, and Miyamae, Takako
- Subjects
- *
RHEUMATISM , *BEHCET'S disease , *STILL'S disease , *MACROPHAGE activation syndrome , *SJOGREN'S syndrome , *SYSTEMIC lupus erythematosus , *ANTIPHOSPHOLIPID syndrome - Abstract
To optimize patient prognosis, patient needs, including unmet needs, should be adequately assessed. However, such needs are more challenging to report and, consequently, more likely to go unmet compared with the needs reported by physicians. We aimed to determine the appropriate direction of future research on unmet medical needs in rheumatic diseases in Japan by conducting a literature review. We searched PubMed and Web of Science using 23 terms linked to unmet medical needs for major rheumatic diseases in Japan. Further, we collected articles on health-related quality of life and investigated the scales used for assessment, as well as whether the terms "unmet needs" or "unmet medical needs" were used. We identified 949 papers on 10 diseases, including systemic lupus erythematosus, systemic sclerosis, dermatomyositis, juvenile idiopathic arthritis, adult-onset Still's disease, antiphospholipid syndrome, mixed connective tissue disease, Takayasu arteritis, Sjögren's syndrome, and Behçet's disease; 25 of the 949 papers were selected for full-text review. Fifteen articles on five diseases were related to health-related quality of life. The term "unmet needs" was used in only one article. Six out of 15 studies used the 36-item short form survey, whereas the scales used in other studies differed. The optimal treatment plan determined by a physician may not necessarily align with the best interests of the patient. In clinical research, cross sectional and standardized indicators of health-related quality of life should be employed along with highly discretionary questionnaires to assess and optimize resource allocation in healthcare and simultaneously achieve patient-desired outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Editorial Compilation XIV.
- Author
-
Favaloro, Emmanuel J., Pasalic, Leonardo, and Lippi, Giuseppe
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *SARS-CoV-2 - Abstract
The latest issue of Seminars in Thrombosis and Hemostasis (STH) is a compilation of articles covering various topics related to thrombosis and bleeding. It includes reviews on neonates with intrauterine growth restriction, pediatric presentations of the antiphospholipid syndrome, genetic variations in tissue factor-dependent disease, heterozygous factor XIII deficiency, and the use of global hemostasis assays in patients with myeloproliferative neoplasms. The document also features reviews on the role of CD36 in platelet activation, laser-induced blood coagulation in surgery, detecting blood clots in ECMO circuits, post-COVID venous thrombosis, and the effects of SARS-CoV-2 spike protein variants on platelets. Commentaries on various topics and the republishing of historical papers are also included. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. Bibliometric and altmetric analysis of research relating to antiphospholipid syndrome based on VOS viewer (2011–2021).
- Author
-
He, Youxian, Li, Mengxiang, Yu, Hao, Yin, Feng, Zhang, Xue, Yang, Qiuyu, Xie, Xintong, Wei, Guangliang, Chen, Huidong, He, Chengsong, He, Yue, and Chen, Jie
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *BIBLIOMETRICS , *PHOSPHOLIPID antibodies , *AUTOIMMUNE diseases , *HIGH-income countries , *FIBRINOLYTIC agents - Abstract
Background: Antiphospholipid syndrome is an autoimmune disorder characterized by recurrent vascular thrombosis and pregnancy losses in the presence of persistently positive antiphospholipid antibodies. Bibliometric analysis and altmetric analysis are methods of analyzing academic productivity and influence. Currently, the assessment of antiphospholipid syndrome through the above analyses is lacking. This study investigated the quantity and quality of studies in the field of antiphospholipid syndrome and revealed the characteristics of worldwide productivity on this disease by the bibliometric analysis and altmetric analysis. Methods: The terms "APS," "antiphospholipid syndrome," "antiphospholipid-antibody syndrome," and "Hughes syndrome" were searched on the Web of Science Core Collection from January 1, 2011, to December 31, 2021. Original articles and reviews were selected. We set the filters as "English." Results and conclusion: A total of 1818 articles were retrieved from 68 countries, of which 20 met the criteria of major active countries. High-income countries contributed 1341 articles (73.48%). The number of articles annually increased significantly in the 10-year period (P < 0.001). The USA (253, 13.91%) was the most productive country. Adjusted by population, Serbia was top of the list. According to the gross domestic product analysis, Serbia ranked first. The most used keywords such as thrombosis and antiphospholipid antibodies were presented by keywords analyses. A content analysis found antithrombotic and anticoagulant therapy as research hotspots. A significant correlation was detected between average citations and altmetric attention scores (P = 0.002) and Mendeley readers count (P < 0.001). From 2011 to 2021, the number of global articles increased rapidly. Most papers came from high-income countries. The relationship between the bibliometric and altmetric analyses were basically consistent; therefore the two can prove/complement each other. Key points • We revealed the global productivity characteristics of the papers related to antiphospholipid syndrome by using the methods of bibliometric analysis and altmetric analysis. • We found the most selected articles that describe the treatment of antiphospholipid syndrome, especially antithrombotic and anticoagulant treatments, which may be the current research hotspot. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Antiphospholipid syndrome in cardiovascular disease and cancer.
- Author
-
Pessach, Ilias, Kyriakou, Elias, Kalampokas, Emmanouil, Kalampokas, Theodoros, Bitsani, Aikaterini, and Kotsianidis, Ioannis
- Subjects
- *
CARDIOVASCULAR diseases , *ANTIPHOSPHOLIPID syndrome , *LITERATURE reviews , *PHOSPHOLIPID antibodies , *AUTOIMMUNE diseases , *PATIENT monitoring - Abstract
Antiphospholipid syndrome is an autoimmune disorder which is characterized by the presence of heterogeneous antiphospholipid antibodies. There is an evidence on antiphospholipid (aPL) antibodies related to thromboembolic events in cancer patients. In fact, the thrombotic complications in patients with malignancy occur at a rather high frequency, compared to other risk factors. In parallel with standard therapies available, there is need of case‐by‐case monitoring of each patient and the introduction of new therapies and need for more clinical trials which will address many questions for the optimal management of patients. This paper presents a basic review of the literature on the aPL antibodies associated with cardiovascular disease and cancer, as well as its complications, which are reported so far in the bibliography. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications.
- Author
-
Seida, Isa, Alrais, Mahmoud, Seida, Ravend, Alwani, Abdulkarim, Kiyak, Zeynep, Elsalti, Abdulrahman, Nil Esirgun, Sevval, Abali, Tunahan, and Mahroum, Naim
- Subjects
- *
COVID-19 pandemic , *VACCINE manufacturing , *SYSTEMIC lupus erythematosus , *AUTOIMMUNE diseases , *MINERAL oils , *SYNDROMES , *ANTIPHOSPHOLIPID syndrome - Abstract
Summary: Adjuvants, as the name indicates, are adjoined material aimed to assist in functioning as when added to vaccines they are meant to boost the effect and strongly stimulate the immune system. The response of the immune system can be unpredictable, and the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was developed to address possible adverse reactions of an autoimmune and inflammatory type that may be caused by adjuvants. While ASIA, as a syndrome, was coined and defined in 2011; reports describing patients with vague and nonspecific clinical symptoms following vaccinations appeared much earlier. In other words, ASIA came to define, arrange, and unite the variety of symptoms, related to autoimmunity, caused not by the vaccine itself, rather by the adjuvant part of the vaccine such as aluminum, among others. Accordingly, the introduction of ASIA enabled better understanding, proper diagnosis, and early treatment of the disorder. Furthermore, ASIA was shown to be associated with almost all body systems and various rheumatic and autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and systemic sclerosis. In addition, the correlation between COVID-19 and ASIA was noticed during the pandemic. In this review, we summarized the reported effects of adjuvants and medical literature before and after ASIA was defined, the several ways ASIA can manifest and impact different systems of the body, and the incidences of ASIA during the COVID-19 pandemic. It is important to clarify, that vaccines are among, if not the, most effective means of fighting infectious diseases however, we believe that vaccines manufacturing is not above criticism, particularly when it comes to added substances possessing a risk of side effects. Adjuvants such as aluminum, mineral oils, and silicone are added to vaccines in order to trigger a stronger immune response. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was introduced in 2011 to address nonspecific symptoms and disorders appearing following vaccinations, which in fact were reported by many papers before the introduction of the syndrome. During the pandemic of COVID-19, a correlation between ASIA, COVID-19, and COVID-19 vaccines has been reported. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Platelet-Derived Microparticles and Autoimmune Diseases.
- Author
-
Li, Xiaoshuai and Wang, Qiushi
- Subjects
- *
AUTOIMMUNE diseases , *SJOGREN'S syndrome , *SYSTEMIC lupus erythematosus , *ANTIPHOSPHOLIPID syndrome , *PROGNOSIS - Abstract
Extracellular microparticles provide a means of cell-to-cell communication and can promote information exchanges between adjacent or distant cells. Platelets are cell fragments that are derived from megakaryocytes. Their main functions are to stop bleeding, regulate inflammation, and maintain the integrity of blood vessels. When platelets are activated, they can perform related tasks by secreting platelet-derived microparticles that contain lipids, proteins, nucleic acids, and even organelles. There are differences in the circulating platelet levels in many autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid antibody syndrome, and Sjogren's syndrome. In this paper, the latest findings in the research field of platelet-derived microparticles are reviewed, including the potential pathogenesis of platelet-derived microparticles in various types of immune diseases, their potential as related markers, and for monitoring the progress and prognosis of disease treatment are expounded. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. The role of thrombophilias in reproduction: A swot analysis.
- Author
-
Fabregues, Francisco, Antonio García-Velasco, Juan, Llácer, Joaquín, Requena, Antonio, Ángel Checa, Miguel, Bellver, José, and José Espinós, Juan
- Subjects
- *
SWOT analysis , *EMBRYO implantation , *BLOOD coagulation disorders , *HYPERCOAGULATION disorders , *INFERTILITY - Abstract
Thrombophilia is a group of inherited or acquired coagulation disorders that have been associated with reproductive failure. However, there are still no clear recommendations on whether its inclusion in the initial study of the infertile couple or patients with recurrent implantation failure is necessary. In this discussion paper, based on a SWOT (strengths, weaknesses, opportunities, threats) analysis, the different aspects of the repercussions of thrombophilia screening and treatment in reproduction are evaluated. To avoid possible subjectivity in the analysis and results of this study, researchers followed Oxford criteria for the evaluation of evidence. The results from the evaluation of the reviewed bibliography seem to indicate that, pending new evidence, it would be advisable not to include thrombophilia screening in the initial baseline study of the infertile couple. There is no evidence to support a clear association between thrombophilia and implantation failure or infertility. Thrombophilia testing in this setting may increase cost, with minimal potential benefit and lead to inappropriate use of anticoagulants with possible deleterious adverse effects. Future well-designed studies are needed to assess the possible benefit of anticoagulant therapy in infertile thrombophilic patients with implantation failure. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Antisense oligonuleotides influences trophoblasts behaviors by changing LncNR_040117 expression in antiphospholipid antibody syndrome-induced recurrent pregnancy loss.
- Author
-
Wang, Di, Tian, Yijia, Wang, Shan, Li, Yilei, Li, Hao, Jiang, Ning, Xie, Yu, Yu, Mengru, Li, Aihua, Wang, Xietong, and Zhou, Qian
- Subjects
- *
VASCULAR cell adhesion molecule-1 , *ANTIPHOSPHOLIPID syndrome , *PHOSPHOLIPID antibodies , *RECURRENT miscarriage , *C-Jun N-terminal kinases , *MITOGEN-activated protein kinases - Abstract
The primary objective of this study was to explore whether antisense oligonucleotides (ASOs) that reduce LncNR_040117 expression in patients with antiphospholipid antibody syndrome (APS)-induced recurrent pregnancy loss (RPL), and further decrease apoptosis and improve trophoblasts invasion through mitogen-activated protein kinase (MAPK) pathways. This paper aimed to provide a new strategy to treat APS-induced RPL. In this study, we used quantitative reverse transcription-polymerase chain reaction (RT–qPCR) to analyze the expression level of LncNR 040117 in HTR-8/SVneo cells following transfection with ASOs. Then we utilized Western blotting to test the expression levels of interleukin-1β (IL-1β), intracellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and key molecules of MAPK pathways, including the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinases (JNK) and p38. In addition, we examined the HTR-8/SVneo cells apoptosis by cell apoptosis assay, and migration and invasion by transwell antibody assay. Each experiment was repeated three times. The data are presented as the means ± SDs, and statistical comparisons were performed using Student's t-test. p < 0.05 was considered significant. Transfected with ASOs, LncNR_040117 was downregulated in trophoblasts compared with APS-induced RPL patients. And LncNR_040117 low expression induced IL-1β and downstream adhesion molecules ICAM-1 and VCAM-1expression level decreased, as well as MAPK pathways downregulation, including the ERK pathway, JNK pathway and p38/MAPK pathway. Furthermore, all these changes resulted in decreased apoptosis and increased migration and invasion of trophoblasts. This study indicated that ASOs that decrease LncNR_040117 expression can reduce apoptosis and enhance the invasion and migration of trophoblasts by regulating the MAPK pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Aortitis is an under-recognized manifestation of antiphospholipid syndrome: A case report and literature review.
- Author
-
Escoda, Thomas, George, Julia, Jarrot, Pierre-André, Jean, Rodolphe, Mazodier, Karin, Sanderson, Frederick, Poullin, Pascale, Saby, Ludivine, Jourde-Chiche, Noémie, Kaplanski, Gilles, and Chiche, Laurent
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *AORTITIS , *SYSTEMIC lupus erythematosus , *PHOSPHOLIPID antibodies , *LITERATURE reviews , *AUTOIMMUNE diseases - Abstract
Aortitis is a classic manifestation of large vessel vasculitis. Antiphospholipid syndrome (APS), sometimes known as Hughes syndrome, is an acquired autoimmune disorder that manifests clinically as recurrent venous or arterial thrombosis. Patients with APS may also suffer from various underlying diseases, most frequently systemic lupus erythematosus (SLE). Catastrophic antiphospholipid syndrome (CAPS) is a rare but serious complication of APS characterized by failure of several organs due to diffuse microcirculatory thrombi. Its main manifestations involve the kidneys, lungs, heart and central nervous system, and require early diagnosis and rapid therapeutic management. While APS can affect virtually any blood vessel, aortitis is not a known symptom of APS. We report the case of a 36-year-old patient with APS and SLE who presented with CAPS during pregnancy, with no concomitant SLE flare. The first manifestation of CAPS was aortitis, preceding renal, cardiac and haematological manifestations. The outcome was favourable with combined treatment including corticosteroids, anticoagulants, plasma exchange and rituximab. We then carried out a literature search for papers describing the presence of aortitis in APS and/or SLE. In the cases of aortic involvement identified in the literature, including another case of CAPS, the occurrence of aortitis in SLE, often associated with the presence of antiphospholipid antibodies/APS, suggests that aortitis should be considered as an under-recognized manifestation and potential non-criterion feature of APS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. The spectrum of complement pathway activation is integral to the pathogenesis of severe COVID-19.
- Author
-
Magro, Cynthia and Nuovo, Gerard
- Subjects
- *
COMPLEMENT activation , *ANTIPHOSPHOLIPID syndrome , *COVID-19 , *SARS-CoV-2 , *HEMOLYTIC-uremic syndrome - Abstract
We read with interest the paper by Lee I et al i .[1] in which they describe widespread microvascular damage marked by endothelial cell damage/activation, microthrombi, complement activation, and disruption of the blood-brain barrier (BBB). Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
16. A maternal death due to the intracerebral hemorrhage caused by antiphospholipid syndrome: a case report.
- Author
-
Keikhaei, Bijan, Saadati, Najmieh, Mahmoudian-Sani, Mohammad-Reza, and Varnaseri, Mehran
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *CEREBRAL hemorrhage , *COMPUTED tomography , *CAUSES of death , *HOSPITAL admission & discharge , *GROIN pain - Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the presence of antiphospholipid antibodies in patients with arterial or venous thrombosis or pregnancy complications. This paper reports a case of a 31-year-old woman who died after she underwent C-section for intrauterine fetal death (IUFD) at the 25th week of gestation. The patient was complaining of pelvic pressure, swelling in the lower limbs, and pain in the groin, one big toe, and both wrists. She had low platelet count, liver abnormalities, and proteinuria. After IUFD, she complained of flank pain and headache. After discharge from the hospital, the patient had constant headaches and 5 days later woke up with hemiplegia. CT scan showed cerebral hemorrhage in the right hemisphere and thrombosis in the left hemisphere. The LA and APS tests were positive. The main cause of death was hemorrhage and infarction in the brain. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Perinatal complications related to inherited thrombophilia: review of evidence in different regions of the world.
- Author
-
Dugalic, Stefan, Petronijevic, Milos, Stefanovic, Aleksandar, Stefanovic, Katarina, Perovic, Milan, Pantic, Igor, Vrzic Petronijevic, Svetlana, Stanisavljevic, Dejana, and Zaric, Milica
- Subjects
- *
HYPERCOAGULATION disorders , *PREGNANCY complications , *PREGNANCY outcomes , *ANTIPHOSPHOLIPID syndrome , *THROMBOEMBOLISM - Abstract
The term thrombophilia describes disorders associated with an increased predisposition of developing venous thromboembolism (VTE). It may be acquired, like in those with antiphospholipid syndrome or inherited. The aim of this review was to compare the complications and outcomes of pregnancies in women with inherited thrombophilia between different populations, including the population of our country where the results of the research are scarce. The review of literature included all papers indexed on PubMed and Medline in the last 20 years, with different study design, including other reviews of literature, systematic reviews with meta-analysis and several case-control studies and population-based cohort studies. We aimed to cover as many geographic regions as possible with the aim to show the differences in the different parts of the world and including our country. Our analysis showed that types of thrombophilia differ in different geographic regions. Also, the differences exist between one particular type of thrombophilia in different regions. Nevertheless, no matter what the differences are between prevalence, all authors investigated the association between inherited thrombophilia and poor pregnancy outcome and managed to find some kind of association. The case with our own country is similar. Although we lack in studies with this issue and the design of published studies is not powerful enough, we may conclude that in our samples, women with thrombophilia are in potential risk of several poor pregnancy outcomes. Further and better analyses are necessary to prove this hypothesis not only on the level of study sample but also on general population. Given the fact that thrombophilia certainly affects the pregnancy and its outcome, the urge to perform screening tests in every woman suspected to have this kind of disorder and with respect to differences that exist in different world regions is inevitable. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Coronavirus-disease-2019-induced antiphospholipid-like syndrome: a case report.
- Author
-
Bahramnezhad, Fatemeh, Ghorbani, Banafsheh, Ghaedrahamt, Meysam, and Jamaati, Hamidreza
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *COVID-19 , *CORONARY artery bypass , *COMPUTED tomography , *MITRAL valve surgery , *PHOSPHOLIPID antibodies - Abstract
Background: This paper describes a case of antiphospholipid syndrome-like condition caused by coronavirus disease 2019. The medical community still faces many diagnostic and therapeutic challenges vis-à-vis coronavirus disease 2019. Ultimately, coronavirus disease 2019 is diagnosed on the basis of laboratory and radiological findings. Considering the high rate of mortality due to coagulation abnormalities and thrombosis among coronavirus disease 2019 patients, it is important to pay attention to the differential diagnoses of coronavirus disease 2019 and other diseases following thrombotic events.Case Description: The patient was a 56-year-old Iranian man who underwent coronary artery bypass graft surgery and mitral valve repair. During hospitalization, the patient showed an elevated level of anticardiolipin antibody (immunoglobulin G isotype), antiphospholipid antibodies, and thrombosis in the brachial artery of the left hand, based on which a differential diagnosis of antiphospholipid syndrome was made. However, ultimately, the coronavirus disease 2019 polymerase chain reaction test and computed tomography scan of the lungs showed that the patient had coronavirus disease 2019.Conclusion: According to the few studies performed on coronavirus disease 2019 patients, elevated levels of the isotypes of antiphospholipid antibodies in coronavirus disease 2019 patients create conditions similar to antiphospholipid syndrome, which, in the absence of reliable coronavirus disease 2019 testing, can lead to misdiagnosis and consequently delayed or improper treatment. Therefore, to provide timely and appropriate treatment, it is important to pay attention to differential diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome.
- Author
-
Zou, Xiaojuan, Fan, Zhongqi, Zhao, Ling, Xu, Weiling, Zhang, Jin, and Jiang, Zhenyu
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *SYMPTOMS , *ANTICARDIOLIPIN antibodies , *PHOSPHOLIPID antibodies , *BLOOD proteins , *DIAGNOSIS - Abstract
Background: Antiphospholipid syndrome (APS) is an acquired pre-thrombotic autoimmune condition, which produces autoantibodies called antiphospholipid antibodies (APL) against phospholipid-binding plasma proteins. The diagnosis of APS requires at least one of Sapporo standard clinical manifestations and one laboratory criteria (persistently medium/high titer anticardiolipin antibodies, and/or medium/high titer anti-β2-glycoprotein I antibodies, and/or a positive lupus anticoagulant test). Gastrointestinal lesions are rarely reported in APS patients. APS cases with recurrent abdominal pain as the first clinical manifestation are even rarer.Case Presentation: This report describes an APS case with recurrent abdominal pain as the first clinical manifestation of antiphospholipid syndrome. The patient has a history of two miscarriages. Computed tomography of the abdomen confirmed mesenteric thrombosis and intestinal obstruction while laboratory tests for serum antiphospholipid and anti-β2-glycoprotein I antibodies were positive. This led to the diagnosis of APS.Conclusions: This paper provides useful information on gastrointestinal manifestations and APS, also including a brief literature review about possible gastrointestinal symptoms of APS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Development of a certified reference material for anti-β2-glycoprotein I IgG – commutability studies.
- Author
-
Monogioudi, Evanthia, Martos, Gustavo, Sheldon, Joanna, Meroni, Pier Luigi, Trapmann, Stefanie, and Zegers, Ingrid
- Subjects
- *
REFERENCE sources , *HIGH-risk pregnancy , *ENZYME-linked immunosorbent assay , *ANTIPHOSPHOLIPID syndrome , *PREGNANCY complications - Abstract
Objectives: In this paper, we describe the steps followed for the development of a certified reference material for immunoglobulin G antibodies against β2-glycoprotein I (also known as apolipoprotein H). These steps include processing of the material, commutability, the impact of dilution, the appropriate reconstitution conditions, homogeneity and stability during transport and storage. Methods: We analysed 69 clinical samples from patients suffering from antiphospholipid syndrome with several commercial enzyme-linked immunosorbent assays (ELISA) purchased from in vitro diagnostic manufacturers. Results: Analysis of the results indicated that the candidate reference material can be safely freeze-dried, and that the user should carefully follow the reconstitution instructions as small changes in e.g. temperature may have unwanted effects. The statistical analysis of the commutability studies indicated that the analytical response of the reference material upon dilution is similar to that of clinical samples, and that correlation between results may differ from assay to assay. Finally yet importantly, the presented and developed candidate reference material is commutable for most assays tested, homogeneous and stable. Conclusions: Immunoglobulin G antibodies against β2-glycoprotein I are associated with a higher risk of thrombosis and pregnancy complications. Their measurement is essential for the diagnosis and monitoring of antiphospholipid syndrome. These antibodies are detected by specific immunoassays, routinely used in clinical diagnostics, but various of these methods show enormous variability, in part due to the lack of a reference material. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Nephrotic syndrome in the course of type 1 diabetes mellitus and systemic lupus erythematosus with secondary antiphospholipid syndrome - diagnostic and therapeutic problems.
- Author
-
Graca, Aleksandra, Suszek, Dorota, Jeleniewicz, Radosław, and Majdan, Maria
- Subjects
- *
SYSTEMIC lupus erythematosus , *TYPE 1 diabetes , *NEPHROTIC syndrome , *LUPUS nephritis , *ANTIPHOSPHOLIPID syndrome , *SYMPTOMS , *RENAL biopsy - Abstract
Nephrotic syndrome (NS) can be a symptom of many autoimmune, metabolic, or infectious diseases. Kidney involvement is often observed in the course of diabetes mellitus (DM) and systemic lupus erythematosus (SLE). The development of NS with coexisting SLE and DM generates serious diagnostic problems. In this paper, the authors present diagnostic and therapeutic dilemmas in a patient with long-lasting DM, SLE, and secondary antiphospholipid syndrome, in whom NS symptoms appeared. Histopathological examination of the kidney confirmed the diagnosis of lupus nephritis. Immunosuppressive and anticoagulant drugs were used. The authors demonstrated that the character of morphologic lesions in the kidney biopsy can help in diagnosis, nephropathy classification, and further therapeutic decisions, which are distinct in both diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center.
- Author
-
Serrano, Rosa, Pons-Estel, Guillermo J, Espinosa, Gerard, Quintana, Rosana M., Reverter, Joan C, Tassies, Dolors, Monteagudo, Joan, and Cervera, Ricard
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *VENOUS thrombosis , *FETAL development , *AUTOIMMUNE diseases - Abstract
Objective: The objective of this paper is to assess the prevalence of the main clinical manifestations and laboratory features at disease onset and during the ensuing 10 years of a large cohort of patients with antiphospholipid syndrome (APS) from a single center. Methods: The study included all consecutive APS patients followed longitudinally in our center from 2003 to 2013. Descriptive statistics for demographics, clinical and laboratory features and mortality were performed. Results: A total of 160 patients were included. Most of them, 128 (78.8%), were women and the mean (SD) age at diagnosis was 39.1 (14.0) years. The majority of them, 104 (65.0%), had primary APS, 36 (22.5%) had APS associated with systemic lupus erythematous, and 20 (12.5%) had APS associated with other autoimmune disease. During the study period, thrombotic events occurred in 27 (16.9%) patients, the most common being strokes, nonbacterial thrombotic endocarditis and deep venous thrombosis. Regarding obstetric morbidity, 18 women (14.3%) became pregnant and 90% of pregnancies succeeded in having live births. The most common obstetric complication was early pregnancy loss (15% of pregnancies). Prematurity (11.1% of live births) and intrauterine growth restriction (5.6% of live births) were the most frequent fetal morbidities. Ten (6.3%) patients died and the most frequent causes of death were severe thrombosis, hemorrhage, and cancer. Three (0.9%) cases of catastrophic APS occurred. The survival probability at 10 years was 93.8%. Conclusions: Patients with APS develop significant morbidity and mortality despite current treatment. It is imperative to identify prognostic factors and therapeutic measures to prevent these complications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus.
- Author
-
Reshetnyak, T. M., Cheldieva, F. A., Cherkasova, M. V., Glukhova, S. I., Lila, A. M., and Nasonov, E. L.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *SYSTEMIC lupus erythematosus , *IMMUNOGLOBULINS - Abstract
An Erratum to this paper has been published: https://doi.org/10.1134/S160767292305006X [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Erratum to: Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus.
- Author
-
Cheldieva, F. A., Reshetnyak, T. M., Shumilova, A. A., Nurbaeva, K. S., Cherkasova, M. V., Lila, A. M., and Nasonov, E. L.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *SYSTEMIC lupus erythematosus - Abstract
An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050046 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Treatment of antiphospholipid syndrome beyond anticoagulation.
- Author
-
Dobrowolski, Chrisanna and Erkan, Doruk
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *PHOSPHOLIPID antibodies , *ADVANCED planning & scheduling , *RAPAMYCIN , *RITUXIMAB , *THERAPEUTICS - Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the present time, treatment is primarily focused on anticoagulation. However, there is increasing awareness of the mechanisms involved in APS pathogenesis, which has led to the trial of novel therapies targeting those mechanisms. Following a brief review of the etiopathogenesis of and current management strategies in APS, this paper focuses on the evidence for these potential, targeted APS treatments, e.g., hydroxychloroquine, statins, rituximab, belimumab, eculizumab, defibrotide, sirolimus, and peptide therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Natural joints: Boundary lubrication and antiphospholipid syndrome (APS).
- Author
-
Pawlak, Zenon, Mrela, Aleksandra, Kaczmarek, Mariusz, Cieszko, Mieczyslaw, and Urbaniak, Wieslaw
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *BOUNDARY lubrication , *SYNOVIAL fluid , *OSTEOPOROSIS , *ARTICULAR cartilage , *GLYCOPROTEINS - Abstract
Graphical abstract Highlights • Lipid profiles of injured and healthy knees' synovial fluids show significant differences. • Osteoporosis changes the SF content and the lipid profile substantially. • An increase in phospholipids over the fractured ones and in the lysophosphatidylcholine levels was observed. • The frictional behavior of the solid bilayer lubricant is dominated by lamellar slippage of bilayers. • The high concentration of PL during inflammation (APS) is of secondary importance in the frictional behavior. Abstract The paper shows that osteoporosis (OA) changes the SF content and the lipid profile substantially. To estimate the implication of the lipid environment in case the articular cartilage (AC) changes, we measured friction coefficient normal samples, with early and late stages of (OA). During joint inflammation and osteoarthritis, enzymatically activated β 2 -Glycoprotein I is transformed into antibody conformation. Our hypothesis about cartilage degradation of PL bilayers by antibodies (β 2 -Glycoprotein I) is considering antiphospholipid syndrome (APS), which was not discussed in the literature before. Deactivated PL molecule has no ability to form bilayers, lamellar phases, and liposomes. The phospholipid content in synovial fluid (SF) during joint inflammation, osteoarthritis, and rheumatoid arthritis is significantly higher (2–3 times) above the normal concentration of PL, and has a poor boundary-lubricating ability is deactivated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Hot Topics VI.
- Author
-
Favaloro, Emmanuel J.
- Subjects
- *
THROMBOSIS , *THROMBOEMBOLISM , *ANTIPHOSPHOLIPID syndrome - Abstract
The article introduces various papers published within the issue, including one on thrombosis as a major contributor to global disease burden, another on venous thromboembolism (VTE) in tropical Australia and in indigenous Australians and a paper on antiphospholipid syndrome (APS).
- Published
- 2014
- Full Text
- View/download PDF
28. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.
- Author
-
Abdel-Wahab, N., Talathi, S., Lopez-Olivo, M. A., and Suarez-Almazor, M. E.
- Subjects
- *
PHOSPHOLIPID antibodies , *ANTIPHOSPHOLIPID syndrome , *VIRUS diseases , *SYSTEMATIC reviews , *META-analysis , *DISEASE risk factors - Abstract
Objective: The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method: We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results: We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6-19.4), as were those with HCV (RR 6.3, 95% CI 3.9-10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8-9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4-22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0-22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3-2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3-3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0-18.1), and HBV (5.9%, 95% CI 2.0-11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78-45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions: Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome.
- Author
-
Sahin, S., Adrovic, A., Barut, K., Canpolat, N., Ozluk, Y., Kilicaslan, I., Caliskan, S., Sever, L., and Kasapcopur, O.
- Subjects
- *
SYSTEMIC lupus erythematosus , *ANTICARDIOLIPIN antibodies , *ANTIPHOSPHOLIPID syndrome , *PHOSPHOLIPID antibodies , *AUTOIMMUNE diseases - Abstract
Objectives This paper aims to assess in a retrospective fashion the clinical and laboratory features, severity and outcome of juvenile systemic lupus erythematosus (jSLE) from a referral center in Turkey. Methods We have included all jSLE patients (n = 92) diagnosed according to the revised American College of Rheumatology 1997 criteria between January 2004 and January 2017. Results The most prevalent clinical feature in our cohort was mucocutaneous manifestations (97.8%), followed by constitutional (81.5%), hematological (59.8%) and musculoskeletal manifestations (56.5%). Renal involvement was observed in 38% (n = 35) of the patients, whereas biopsy-proven lupus nephritis was detected in 29.3% (n = 27) of the cohort. Neurologic involvement was seen in 15 (16.3%) individuals. Among the patients positive for anticardiolipin IgM and/or IgG (n = 11, 12%), only three developed antiphospholipid antibody syndrome. The mean SLEDAI-2K scores at disease onset (10.5 ± 4.8) showed a substantial decrease at last visit (4.3 ± 4.6). One-quarter of the patients (26.1%, n = 24) had damage according to the PedSDI criteria with a mean score of 0.45 ± 1.0 (range 0–7). When the PedSDI damage items were evaluated individually, growth failure was the most frequent damage criterion (n = 6), followed by seizure (n = 5). Two patients died during the designated study period of end-stage renal disease. The five-year and 10-year survival rate of our cohort was 100% and 94.4%, respectively. Conclusions Given the lower frequency of nephritis and central nervous system disease and lower basal disease activity and damage scores, we could conclude that children with jSLE in Turkey have a more favorable course compared to Asian and African American children, as expected from Caucasian ethnicity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. ALTERNATIVE ANTICOAGULATION THERAPIES FOR ANTIPHOSPHOLIPID SYNDROME - A NEW THERAPEUTIC CHALLENGE.
- Author
-
Mazilu, Diana and Opris-Belinski, Daniela
- Subjects
- *
ANTIPHOSPHOLIPID syndrome treatment , *ANTICOAGULANTS , *INDIVIDUALIZED medicine , *VITAMIN K , *THROMBOSIS prevention , *VITAMIN therapy ,THROMBOEMBOLISM treatment - Abstract
The major treatment issues in Antiphospholipid Syndrome (APS) include the the prevention of first thrombosis, the treatment of acute thromboembolic manifestations, the choice of anticoagulation, the duration of anticoagulation and secondary thrombosis prevention. Anticoagulation should individualized to the patient and clinical setting. Clasical anti vitamin K antagonists, warfarin and acenocumoral, carry some risks and disadvantages. Direct thrombin inhibitor and direct anti-Xa inhibitors are currently available and were approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation, for the treatment of deep vein thrombosis (DVT) and for the prevention of recurrent DVT and pulmonary embolism. Besides many case series reports, there are ongoing clinical trials testing their efficiency and safety in patients with APS. In this paper we reviewed the advantages, risks and disadvantages for the use of direct oral anticoagulants in this category of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. The antiphospholipid syndrome: from pathophysiology to treatment.
- Author
-
Negrini, Simone, Pappalardo, Fabrizio, Murdaca, Giuseppe, Indiveri, Francesco, and Puppo, Francesco
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *HYPERCOAGULATION disorders , *THROMBOSIS , *PHOSPHOLIPID antibodies , *MONOCLONAL antibodies - Abstract
Antiphospholipid antibody syndrome (APS) is an autoimmune acquired thrombophilia characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). APS can be primary, if it occurs in the absence of any underlying disease, or secondary, if it is associated with another autoimmune disorder, most commonly systemic lupus erythematosus. The exact pathogenetic mechanism of APS is unknown, but different, not mutually exclusive, models have been proposed to explain how anti-PL autoantibodies might lead to thrombosis and pregnancy morbidity. Diagnosis of APS requires that a patient has both a clinical manifestation (arterial or venous thrombosis and/or pregnancy morbidity) and persistently positive aPL, but the clinical spectrum of the disease encompasses additional manifestations which may affect every organ and cannot be explained exclusively by a prothrombotic state. Treatment for aPL-positive patients is based on the patient's clinical status, presence of an underlying autoimmune disease, and history of thrombotic events. In case of aPL positivity without previous thrombotic events, the treatment is mainly focused on reduction of additional vascular risk factors, while treatment of patients with definite APS is based on long-term anticoagulation. Pregnancy complications are usually managed with low-dose aspirin in association with low molecular weight heparin. Refractory forms of APS could benefit from adding hydroxychloroquine and/or intravenous immunoglobulin to anticoagulation therapy. Promising novel treatments include anti-B cell monoclonal antibodies, new-generation anticoagulants, and complement cascade inhibitors. The objective of this review paper is to summarize the recent literature on APS from pathogenesis to current therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Cognitive disorders and antiphospholipid antibodies.
- Author
-
Yelnik, Cécile M., Kozora, Elizabeth, and Appenzeller, Simone
- Subjects
- *
PHOSPHOLIPID antibodies , *COGNITION disorders , *SYSTEMIC lupus erythematosus , *MILD cognitive impairment , *AUTOIMMUNE diseases - Abstract
Cognitive disorders have frequently been described in the field of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Nevertheless, the relationship between those disorders and antiphospholipid antibodies (aPL) remains unclear and seems to involve various mechanisms. Overlap with systemic lupus erythematosus, the small sample size of studies, and discrepancies in antiphospholipid antibodies and cognitive impairment determinations complicate analyses of the literature data. In this paper, we summarize current knowledge on epidemiologic, clinical data, imaging findings and treatment of cognitive dysfunction associated with aPL. We separately analyzed data on aPL-positive carriers without history of clinical feature of APS, APS patients without overlaps autoimmune disease, and SLE-associated aPL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Papers to be published in forthcoming issues.
- Subjects
- *
LYMPHOMAS , *INTERLEUKIN-5 , *TUMORS , *DRUG therapy , *CANCER , *ANTIPHOSPHOLIPID syndrome , *HODGKIN'S disease - Abstract
The article presents lists of forthcoming issues including "T-cell Lymphoblastic Lymphoma Presenting as an intra-muscular mass," by Z.-Y. Lim, S. Gupta, J. R. Salisbury, D. Elias, N. Venkatram, G. J. Mufti and A. Pagliuca, "Unusual Manifestations of Catastrophic Antiphospholipid Syndrome in the Abdomen," by D. C. L. Tan, A. H. L. Low, H. S. Ong, Y. C. Linn and J. Thumboo, "Towards Targeted Therapy for Infant Acute," by R. W. Stam, M. L. den Boer and R. Pieters, "Obtaining Consent for Chemotherapy," by J. Treleaven, J. O. Cullis, R. Maynard, E. Bishop, I. Ainsworth-Smith, A. Roques, A. Webb, J. Favre and D. Milligan and "cFLIP Expression Correlates with Tumour Progression and Patient Outcome in non Hodgkin Lymphomas of Low-Grade of Malignancy," by G. Valente, F. Manfroi, C. Peracchio, G. Nicotra, R. Castino, G. Nicosia, S. Kerim and C. Isidoro
- Published
- 2006
- Full Text
- View/download PDF
34. Musculoskeletal manifestations of the antiphospholipid syndrome.
- Author
-
Noureldine, M. H. A., Khamashta, M. A., Merashli, M., Sabbouh, T., Hughes, G. R. V., and Uthman, I.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *DISEASE complications , *MUSCULOSKELETAL system diseases , *QUALITY of life , *SYMPTOMS - Abstract
The scope of clinical and laboratory manifestations of the antiphospholipid syndrome (APS) has increased dramatically since its discovery in 1983, where any organ system can be involved. Musculoskeletal complications are consistently reported in APS patients, not only causing morbidity and mortality, but also affecting their quality of life. We reviewed all English papers on APS involvement in the musculoskeletal system using Google Scholar and Pubmed; all reports are summarized in a table in this review. The spectrum of manifestations includes arthralgia/arthritis, avascular necrosis of bone, bone marrow necrosis, complex regional pain syndrome type-1, muscle infarction, non-traumatic fractures, and osteoporosis. Some of these manifestations were reported in good quality studies, some of which showed an association between aPL-positivity and the occurrence of these manifestations, while others were merely described in case reports. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome.
- Author
-
Kitaori, T., Sugiura-Ogasawara, M., Oku, K., Papisch, W., Ebara, T., Ozaki, Y., Katano, K., and Atsumi, T.
- Subjects
- *
PHOSPHOLIPID antibodies , *ANTIPHOSPHOLIPID syndrome , *RECURRENT miscarriage , *ANTICOAGULANTS , *IMMUNOGLOBULIN G - Abstract
Objective The objective of this paper is to determine which kinds of assays for antiphospholipid antibodies (aPL) should be tested for clinical practice for patients with recurrent pregnancy loss (RPL). Materials and methods We studied 560 patients with a history of RPL prospectively. We determined the obstetric significance of 11 commercially available tested assays for lupus anticoagulant (LA)-aPTT StaClot, phosphatidylserine-dependent antiprothrombin (aPS/PT) IgG, IgM, classical cardiolipin (CL) IgG, IgM, CL IgG, IgM, IgA, and β2glycoprotein I (β2GPI) IgG, IgM, IgA Phadia. Obstetric significance was defined as the potential for anticoagulant therapy to improve the subsequent live birth rate, or a difference in the live birth rate between positive and negative untreated cases. Results The LA-aPTT StaClot assay and aPS/PT IgG assay, but not CL IgG, were found to have obstetric significance. Our conventional tests covered positive cases with the aPS/PT IgM and classical CL IgG assays. The results of the LA-aPTT StaClot, LA-aPTT and LA-RVVT assays showed different distributions, although strong or moderate correlation was observed. Conclusion LA-aPTT StaClot and aPS/PT IgG might be suitable for use in routine practice for patients with RPL. Each test for aPL should be ascertained for obstetric significance, because similar assays may have different outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS.
- Author
-
McDonnell, Thomas, Pericleous, Charis, Laurine, Emmanuelle, Tommasi, Rita, Garza-Garcia, Acely, Giles, Ian, Ioannou, Yiannis, and Rahman, Anisur
- Subjects
- *
PROTEIN expression , *GLYCOPROTEIN genetics , *DISEASE progression , *ANTIPHOSPHOLIPID syndrome , *AUTOANTIBODIES , *N-terminal residues , *GENETICS - Abstract
Background: In this paper we describe a novel method to achieve high yield bacterial expression of a small protein domain with considerable therapeutic potential; Domain I of Beta-2-glycoprotein I (β2GPI). β2GPI is intrinsic to the pathological progression of the Antiphospholipid Syndrome (APS). Patients develop autoantibodies targeting an epitope located on the N-terminal Domain I of β2GPI rendering this domain of interest as a possible therapeutic. Results: This new method of production of Domain I of β2GPI has increased the production yield by ~20 fold compared to previous methods in E.coli. This largely scalable, partially automated method produces 50-75 mg of pure, folded, active Domain I of β2GPI per litre of expression media. Conclusion: The application of this method may enable production of Domain I on sufficient scale to allow its use as a therapeutic. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).
- Author
-
Amigo, M-C, Goycochea-Robles, M. V., Espinosa-Cuervo, G., Medina, G., Barragán-Garfias, J. A., Vargas, A., and Jara, L. Javier
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *PROGNOSIS , *DELPHI method , *QUALITY of life , *CRONBACH'S alpha , *PATIENTS - Abstract
Introduction In antiphospholipid syndrome (APS), certain principal manifestations are associated with a worse prognosis and organ damage. Objective The objective of this paper is to describe the development and initial content, criterion and construct validity of a disease-specific cumulative damage index in patients with thrombotic APS (DIAPS). Methods Through expert panel agreement, 47 items were considered to reflect damage in APS. This preliminary version of the DIAPS was submitted to four local and international clinical and research experts in APS who ranked each item according to severity. A Delphi exercise resulted in a final 37 item instrument. In the second phase, a cross-sectional study was conducted applying the DIAPS in patients included in a multicenter electronic registry of patients with APS. Quality of life related to health status was evaluated with the EuroQol for construct validation. An α Cronbach and correlation with the EuroQol scale were calculated with SPSS 20.0 (p < 0.05). Results We evaluated the DIAPS in 156 patients, 77% female, with a mean age at diagnosis 34.7 ± 5.5 years. A total of 69% had primary APS. Common comorbidities included obesity, depression and dyslipidemia. The most frequent manifestations resulting in sequelae were deep venous thrombosis and ischemic stroke. Blindness, retinal occlusive vessel disease, myocardial infarction, cardiac valve requiring replacement, mesenteric thrombosis, and renal insufficiency also occurred. Homogeneity: α Cronbach 0.619. DIAPS items correlated with EuroQol domains with the exception of pulmonary, renal, gastrointestinal, and endocrine systems. Conclusion This study demonstrates content, criterion and construct validity of a new physician-reported instrument to assess the DIAPS. In addition, the DIAPS correlated with the EuroQol. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
38. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.
- Author
-
Chighizola, C. B., Andreoli, L., de Jesus, G. Ramires, Banzato, A., Pons-Estel, G. J., and Erkan, D.
- Subjects
- *
PHOSPHOLIPID antibodies , *ANTIPHOSPHOLIPID syndrome , *EPIDEMIOLOGY , *PREGNANCY complications , *MYOCARDIAL infarction - Abstract
In a previous systematic literature search, we demonstrated that the frequencies of antiphospholipid antibodies (aPL) in general-population patients with pregnancy morbidity (PM), deep vein thrombosis (DVT), myocardial infarction (MI), and stroke (ST) are 6%, 10%, 11%, and 14%. To determine the association between aPL and clinical outcomes, we conducted a follow-up analysis of the 120 studies included in the original paper. Based on the analysis of 81 studies, a significant difference in the frequency of aPL criteria tests between patients and controls emerged considering all the outcomes together (10% versus 3%). In particular, a significant difference was reported for overall PM, pregnancy loss (PrL), late PrL, severe preeclampsia (PEC), ST, MI, and DVT. No difference emerged for early PrL, intrauterine growth restriction (IUGR), PEC, eclampsia (EC), and HELLP. A positive association was found in more than half of the studies for overall PrL, severe PEC, HELLP, ST, MI, and DVT and in less than half for early and late PrL, PEC, EC, and IUGR. The positive association between aPL and clinical outcomes included in the antiphospholipid syndrome classification criteria is not supported by every study, being particularly inconsistent for early PL, IUGR, PEC, EC, and HELLP. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
39. Hughes syndrome and Multiple sclerosis.
- Author
-
Uthman, I, Noureldine, M H A, Berjawi, A, Skaf, M, Haydar, A A, Merashli, M, and Hughes, G R V
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *MYELIN sheath diseases , *DEMYELINATION , *MUSCULOSKELETAL system , *ELASTIC tissue - Abstract
Multiple sclerosis (MS) and antiphospholipid syndrome (APS) share common clinical, laboratory and radiological features. We reviewed all the English papers on MS and APS published in the literature from 1965 to 2014 using PubMed and Google Scholar. We found that APS can mimic antiphospholipid antibodies (aPL)-positive MS in many ways in its clinical presentation. Nevertheless, APS diagnosis, clinical manifestations and management differ from those of MS. aPL were found in MS patients with titers ranging from 2% to 88%. The distribution and volume of lesions on magnetic resonance imaging (MRI) may help to differentiate MS from primary APS. In addition, atypical MS presentation can guide physicians toward an alternative diagnosis, especially when features of thrombosis and/or history of connective tissue disease are present. In that case, an anticoagulation trial could be worthwhile. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes.
- Author
-
Nalli, C, Iodice, A, Andreoli, L, Lojacono, A, Motta, M, Fazzi, E, and Tincani, A
- Subjects
- *
SYSTEMIC lupus erythematosus , *AUTOIMMUNE diseases , *ANTIPHOSPHOLIPID syndrome , *THROMBOSIS , *IMMUNOGLOBULINS - Abstract
Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease that primarily affects women of childbearing-age. Antiphospholipid syndrome (APS) is a systemic autoimmune disorder defined by the occurrence of venous and arterial thrombosis, often multiple, and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Recently, the long-term outcome of children born to patients with lupus and APS has become a major topic of interest both to patients and physicians. One of the major problems related to maternal disease is preterm delivery with all the consequences that this condition may bring. Prematurity may also be due to the presence of aPL; however, aPL do not generally display any thrombotic potential on neonates. Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB). In addition, behaviour and neuropsychological outcomes have also been a matter of interest, but there are currently few data available. Beyond the biological influence of both maternal disease and autoimmune background, it is important to focus on the possible influence of maternal chronic illness on the neuropsychological development of her children. Whether aPL exposure could have a direct effect on brain development is still being debated. In children of mothers with APS, language delays have been noted and learning disabilities were described with a higher rate than the general age-school population. Several studies were performed on children born to lupus mothers: even if maternal lupus does not seem to impair intelligence levels, it may increase the occurrence of learning disabilities and particularly dyslexia in male children. To the best of our knowledge, no studies are available on the long-term outcome of children born to mothers with lupus or APS and particularly regarding the development of autoimmune diseases. Nevertheless, common experience of experts in the field is that these children do not show a significantly increased risk of displaying the same autoimmune disease as their mothers. The purpose of this paper is to answer the frequently asked questions of patients with lupus and APS who desire to become mothers, based on the little information available. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
41. Anesthetic management of antiphospholipid syndrome patients who underwent cardiac surgery.
- Author
-
Hyunwook Cho, Yunseok Jeon, Deok Man Hong, Hyun Joo Kim, and Jeong Jin Min
- Subjects
- *
ADMINISTRATION of anesthetics , *ANTIPHOSPHOLIPID syndrome , *CARDIAC surgery , *BLOOD coagulation disorders , *THROMBOEMBOLISM , *HEART valve diseases , *CARDIOPULMONARY bypass , *PATIENTS - Abstract
Antiphospholipid syndrome (APS) is a rare disease in which patients display prolonged coagulation test results in vitro, but usually develop thrombotic symptoms in vivo. Patients with APS are at increased risk of valvular heart disease or coronary vascular disease, conditions that often necessitate cardiac surgery via bypass. The management of anticoagulation during cardiopulmonary bypass (CPB) is particularly challenging in these patients because of the unique features of APS. Patients with APS are constantly at risk of arterial and venous thrombotic events. Therefore it is very important to maintain proper anticoagulation perioperatively, especially during CPB. In this paper, we present three successful cases of APS patients who underwent cardiac surgery with CPB. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. Coexistence of renal artery stenosis, primary antiphospholipid syndrome and polycythaemia vera: an exceptional association.
- Author
-
Ha-ou-nou, F Zahra, Boumzebra, D, and Essaadouni, L
- Subjects
- *
ARTERIAL stenosis diagnosis , *CARDIOVASCULAR disease diagnosis , *HYPERTENSION , *ANTIPHOSPHOLIPID syndrome , *BLOOD circulation disorders , *DIAGNOSIS ,RENAL artery diseases - Abstract
Renal artery stenosis is the narrowing of the renal artery which causes hypertension and atrophy of the affected kidney, ultimately leading to renal failure if not treated and most often caused by atherosclerosis or fibromuscular dysplasia. Recently, renal artery stenosis has also been documented in patients with the antiphospholipid syndrome and in very few cases with myeloproliferative disease. In this paper, we describe a 31-year-old female with a history of gangrene affecting the toes with severe hypertension (200/110 mmHg), whose investigations revealed a combination of renal artery stenosis, primary antiphospholipid syndrome and polycythaemia vera. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
43. Antiphospholipid Syndrome.
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *AUTOIMMUNE disease treatment , *WARFARIN , *ANTICOAGULANTS , *DRUG efficacy - Abstract
This article several research being done on the treatment of antiphospholipid syndrome. It references papers published in the journals "Rheumatology," "Ann Rheum Dis" and "Arthritis Rheum" in 2007. The first paper recomemnded prolonged warfarin therapy for antiphospholipid syndrome. The second paper emphasized the importance of a high index of suspicion for any signs of abdominal involvement in patients with the syndrome.
- Published
- 2008
44. Congenital absence of inferior vena cava in a 33-year-old with antiphospholipid antibody syndrome: A case report.
- Author
-
Spooner, Jesse, Ginting, Nadra, and Birk, Manjot
- Subjects
- *
VENA cava inferior , *PHOSPHOLIPID antibodies , *ANTIPHOSPHOLIPID syndrome , *VENOUS thrombosis , *COMPRESSION stockings - Abstract
Background: Agenesis of the inferior vena cava (AIVC) is a rare disorder that, when combined with co-morbid hypercoagulable disease such as antiphospholipid antibody syndrome (APAS), increases the risk of chronic deep vein thrombosis (DVT). We report a 33-year-old female with a past medical history of recurrent DVTs and antiphospholipid antibody syndrome (APAS) who at the age of 33, was incidentally found to have AIVC while assessing clot burden, which likely contributed to her recurrent DVT episodes earlier in life. Management: The combination of AIVC and antiphospholipid antibody syndrome is rare and can lead to recurrent DVTs in young patients. Prolonged anticoagulation is the preferred treatment when used in conjunction with the prescription of compression stockings, modification of risk factors, and treatment of further complications. In this paper we provide a case discussion and up-to-date information on diagnosis and management of a patient with both AIVC and APAS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
45. Causes and predictors of death in Brazilian lupus patients.
- Author
-
Telles, Rosa, Lanna, Cristina, Souza, Fabiana, Rodrigues, Luciana, Reis, Rodrigo, and Ribeiro, Antonio
- Subjects
- *
SYSTEMIC lupus erythematosus , *KAPLAN-Meier estimator , *ATHEROSCLEROTIC plaque , *ANTIPHOSPHOLIPID syndrome , *SYSTOLIC blood pressure - Abstract
The objective of this study is to determine the causes and predictors of death in systemic lupus erythematosus (SLE) patients. Causes of death were defined based on death certificates, medical records, and information collected from doctors and relatives. Possible variables predicting mortality were assessed by Kaplan-Meier and Cox regression methods. The multivariate model was validated using the bootstrap method, and the hazard ratios were adjusted according to the shrinkage coefficient. One hundred eighty-one patients were included, and two patients were lost to follow-up. The median (IR) age at T and disease duration of the 179 patients were 26.7 (21.8-34.6) and 8.2 (4.3-12.4) years, respectively. After a median (IR) follow-up of 3.3 (3.1-3.5) years, 13 (7.3 %) patients died due to end-organ failure (5), infection (5), disease activity (1), and atherosclerotic cardiovascular disease (CVD) (1). The cause of mesenteric ischemia in one patient could not be determined. Predictors of mortality collected at T were the following: nephritis, chronic kidney disease, antiphospholipid syndrome (APS), higher modified SLEDAI-2k, higher damage index score, intravenous cyclophosphamide use, higher daily dose of prednisone, and higher systolic blood pressure. Independent predictors of mortality were higher damage index score (HR: 1.40; 95 % CI: 1.08-1.82), cyclophosphamide use (HR: 3.80; 95 % CI: 1.13-12.77), and APS diagnosis (HR: 3.82; 95 % CI: 1.07-13.59). This paper presents a high frequency of late mortality in lupus patients due to the SLE itself and infection. This result is not in agreement with the initial proposed bimodal pattern of lupus mortality, nor is it in agreement with the high frequency of CVD as a cause of death in developed countries. The most important predictors of death were related to the lupus itself. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
46. Primary prevention in antiphospholipid antibody carriers.
- Author
-
Bertero, MT
- Subjects
- *
PHOSPHOLIPID antibodies , *THROMBOSIS , *PREGNANCY complications , *ASPIRIN , *ORGANS (Anatomy) , *NERVOUS system - Abstract
The discovery of antiphospholipid antibodies (aPL) positivity in individuals who have never experienced thrombosis or pregnancy complications is not a rare event, and is one of the unresolved issues in the field of antiphospholipid syndrome (APS). This paper focuses on primary prophylaxis for thrombotic events in aPL carriers. In our view, patients with high risk aPL profiles and/or other cardiovascular risk factors, concomitant diagnosis of systemic lupus erythematosus (SLE) and patients with an history of obstetric APS (OAPS) should be offered thromboprophylaxis. Chronic thromboprophylaxis with low-dose aspirin and hydroxychloroquine in aPL positive SLE patients should be prescribed both to prevent thrombosis and to avoid early organ damage. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
47. Does seronegative antiphospholipid syndrome really exist?
- Author
-
Cervera, Ricard, Conti, Fabrizio, Doria, Andrea, Iaccarino, Luca, and Valesini, Guido
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *CARDIOLIPIN , *GLYCOPROTEINS , *IMMUNOGLOBULINS , *DISEASE complications , *THROMBOSIS , *DIAGNOSIS - Abstract
Abstract: The diagnosis of seronegative (SN-) antiphospholipid syndrome (APS) has been suggested for patients with clinical manifestations indicative of APS but with persistently negative results in the commonly used assays to detect anti-cardiolipin (aCL) antibodies, anti-β2 Glycoprotein I antibodies (aβ2GPI), and lupus anticoagulant (LA). To date the best management of these patients is still unclear. New emerging anti-phospholipid (aPL) assays could improve our ability in diagnosing APS. However, the availability of aPL assays in routine laboratory practice is limited. In fact, even aβ2GPI is routinely tested in only a small number of laboratories, and other aPL, such as anti-prothrombin or anti-annexin antibodies, in only a few research laboratories. On the other hand transient or false negative aPL assay and other genetic or acquired pro-thrombotic conditions can further complicate this issue. This paper is focused on the arguments for and against the diagnosis of SN-APS and is aimed to help the clinician when approaching a patient with clinical manifestations consistent with APS diagnosis but with negative aPL using the commonly available tests. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
48. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’
- Author
-
Pengo, Vittorio, Ruiz-Irastorza, Guillermo, Denas, Gentian, Andreoli, Laura, Khamashta, Munther, and Tincani, Angela
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *BLOOD coagulation , *THROMBOSIS , *ARTERIAL diseases , *DISEASE relapse , *HEALTH risk assessment , *PREVENTION - Abstract
Abstract: The use of high intensity anticoagulation in the prevention of recurrence of arterial thrombosis related to the Antiphospholipid Syndrome (APS) is still controversial. This paper reports a debate that took place at the CORA meeting (Controversies in Rheumatology and Autoimmunity), held in Florence in March 2011. Major points of discussion were: 1) the paucity of prospective randomized clinical trials; retrospective studies were the main source supporting the use of high intensity anticoagulation; 2) heterogeneity in antiphospholipid antibodies (aPL) definition, due to the lack of standardization of aPL assays and to the failure to distinguish patients with a high risk profile (“triple positive”) from those a low risk profile; 3) bleeding is a major concern about high intensity anticoagulation; however, studies are not concordant in reporting an increased risk compared to the standard regimen; 4) practical issues consist of difficulties in keeping a stable PT-INR over 3 and the possibility for interference by aPL on the thromboplastins used for PT-INR measurement. In conclusion, there is currently a lack of consensus on the use of high intensity anticoagulation for the secondary prophylaxis of arterial thrombosis. However, such a treatment may be particularly recommended in those APS patients who have a high risk aPL profile and other concomitant cardiovascular risk factors, provided that the potential benefit outweighs the risk of bleeding. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
49. Guidelines on the investigation and management of antiphospholipid syndrome.
- Author
-
Keeling, David, Mackie, Ian, Moore, Gary W., Greer, Ian A., and Greaves, Michael
- Subjects
- *
ANTIPHOSPHOLIPID syndrome , *PHOSPHOLIPID antibodies , *GUIDELINES , *THROMBOSIS , *DIAGNOSIS , *PATIENTS - Abstract
The article offers information on antiphospholipid syndrome (APS) and APS management and investigation guidelines. It features a discussion for APS an acquired autoimmune condition which is diagnosed in thrombosis patients or with defined pregnancy morbidity. It discusses the paper published by Galli and colleagues regarding the relation of antiphospholipid antibodies (aPL) and thrombosis.
- Published
- 2012
- Full Text
- View/download PDF
50. Vascular Disease in Systemic Lupus Erythematosus.
- Author
-
Pyrpasopoulou, Athina, Chatzimichailidou, Sofia, and Aslanidis, Spyros
- Subjects
- *
ARTERIOSCLEROSIS risk factors , *ANTIPHOSPHOLIPID syndrome , *HEALTH outcome assessment , *QUALITY of life , *SYSTEMIC lupus erythematosus , *VASCULITIS , *TREATMENT effectiveness , *SEVERITY of illness index - Abstract
Vascular disease, either as a direct complication of the disease or developing as an accompanying comorbidity impairs significantly the quality of life of patients with SLE and represents the most frequent cause of death in established lupus. This paper aims to give an overview of the prevalence of the different forms of vasculopathy that can be encountered in a lupus patient, describe their pathogenesis, and address their impact on disease severity and outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.